19 2010
Ongoing Project Aims to Recover Nutritional Value From Seafood and Brewing Waste
Preliminary findings from a UK government funded project focused on extracting value from seafood and beverage processing waste shows the process could potentially recover nutritional components such as glucosamine.
The process involves an ionic liquid (IL) extraction process which selectively recovers targeted high value components under mild conditions. Ionic Liquids are clean, inexpensive solvents whose properties can be tailored for recovery of specific target molecules. Recycling of recovered components for applications in pharmaceutical, nutraceutical and chemical markets will deliver both economic and environmental benefits to technology adopters.
C-Tech Innovation, a UK based technology development company, is leading the three year EXCIL project that involves collaboration with key stakeholders including Heineken UK, seafood processor West Coast Sea Products, GlycoMar Ltd., the Sea Fish Industry Authority, waste management firm SITA UK and Imperial College London.
The research is being by funded by a UK government agency, the Technology Strategy Board, with the stated objective being to provide a new approach to solving the environmental and financial costs involved in disposal of food and brewing waste through a sustainable and resource efficient method.
EXCIL is a 3 year project which started in October 2009.
16 2010
Ocean Nutrition Canada (ONC) Adds New Omega-3 Microencapsulation Technology to Portfolio
Ocean Nutrition Canada (ONC) has added a new microencapsulation technology to its offerings buy purchasing a five-year license to the fish oil business and encapsulation technology of Austrian tech firm, GAT Food Essentials.
The undisclosed deal will see the Canadian fish oil leader take exclusive rights to GAT’s wowCAPS technology that has proved particularly suitable to dairy formulations, although ONC’s own PowderLoc encapsulation technology has had success there too.
ONC will also take control of GAT’s existing customers in the fish oil space, with there being potential for the two to work together on research and development and formulation.
16 2010
Jellyfish protein boosts cognitive function and wins patent protection
The jellyfish protein apoaequorin improves cognitive function in people with memory problems, according to interim data from a randomized controlled trial commissioned by Quincy BioScience which recently announced a successful application for patent protection. Derived from a jellyfish called Aequorea Victoria, aequorin is a calcium-binding protein.
The protein improved cognitive testing scores by 14 per cent in 60 days compared with the placebo in the randomized controlled Madison Memory Study. The trial focused on 35 adults who had a memory concern and an average age of 61.
The company also recently received a US patent covering the use of aequorin-containing compounds for the purpose of preventing and alleviating symptoms and disorders related to calcium imbalance. It first applied for the patent in 2005.
24 2010
NutritionalFinds to Sell Maritech’s Seaweed Extract Joint Blend in North America
NutritionalFinds.com, a division of Natural Discoveries LLC, announced that they have been granted the exclusive rights to represent Maritech® Joint Blend bioactive for nutraceutical applications in North America. Maritech® Joint blend is a proprietary, certified organic combination of 3 unique fucoidans extracted from seaweed which has been clinically proven safe and effective for reducing the symptoms of osteoarthritis. NutritionalFinds will promote Maritech® as a trademarked raw material for joint health in the U.S. and Canadian markets.
Recent human clinical research (Biologics: Targets & Therapy 2010:4 33-44) conducted at Southern Cross University NatMed Research Centre demonstrated that the natural seaweed extract can reduce osteoarthritis symptoms in some patients by up to 52%. Fucoidans are bioactive polysaccharides thought to be responsible for many of the health benefits attributed to brown seaweeds such as wakame.
26 2010
Novel process allows ‘highest quality’ omega-3 concentrations
Novel technology allows KD-Pharma, the fully-owned subsidiary of health care products company Bioseutica, to produce what it claims to be the market’s safest and highest quality omega-3 concentrations.
Specific combinations of omega-3 EPA/DHA at concentrations of up to 99 percent are produced by the process, known as kd pür, which was designed, developed and patented the company.
This is achieved by advanced super critical fluid technology conducted under mild temperatures below 45 Celsius and under CO2 atmospheric conditions to extract, refine and concentrate highly purified omega-3s from fish oil.
The process is also said to remove other undesired components from omega-3s such as omega-6, saturated fats, cholesterol and contaminants.
07 2010
Maxomega-90 Omega-3 Launch: A ‘Blank Canvas’ For Formulators
Scottish firm Equateq announces today that high-end nutraceutical companies can now provide their customers with almost any ratio of EPA and DHA omega oil concentrates they want, with the launch of Maxomega-90, a range that exploits pharmaceutical sector separation methods to deliver omega-3 EPA and DHA in any 90% combination, Equateq announced today.
‘We say that Maxomega-90 is like a blank canvas, allowing companies to mix lipid actives in almost any combination they require,’ explained Equateq CEO Adam Kelliher. ‘This will enable companies to define their product rationale and give a more clear, and focused offering.’
Lipid specialist Equateq is unique in using industrial-scale chromatography to make lipid concentrates, in preference to the usual industry method of distillation. The Maxomega ™ process can separate all key lipids at up to 99% purity, but these super-high levels are mostly used by pharmaceutical companies and researchers. The Maxomega-90 range is geared for the nutritional sector, allowing delivery of EPA and DHA in any ratio, from 80/10 to 10/80, with each offering always having at least 90% total omega-3.
04 2010
New Microalgal Strain Found with High PUFA Levels
Ben-Gurion University of the Negev (BGU) researchers have isolated a microalgal strain which produces large amounts of a polyunsaturated fatty acid that could reduce blood pressure, chronic inflammation and blood cholesterol level, reducing the risk for heart attacks.
A research team at BGU’s Landau Family Microalgal Biotechnology Lab in the Jacob Blaustein Institutes for Desert Research (BIDR) headed by Prof. Zvi HaCohen, is studying an algal mutant that is capable of accumulating up to 15 percent (of dry weight) of a polyunsaturated fatty acid (PUFA) called DGLA (Dihomo-γ-Linolenic Acid). The new strain, IKG-1, is a freshwater microalga that the researchers believe is the only known plant source capable of producing such significant amounts of DGLA.
04 2010
Valensa International Recognized by Frost & Sullivan for Promoting Astaxanthin as an Eye Health Ingredient
Based on its recent analysis of the eye health astaxanthin market, Frost & Sullivan recognizes Valensa International with the 2009 North American Frost & Sullivan Award for Customer Value Enhancement. Valensa has expanded the market for astaxanthin by positioning its Zanthin® Natural Astaxanthin product as an eye health ingredient and not just an anti-oxidant for general well-being. It holds the Tso Patent, which allows it to promote the use of astaxanthin for eye health support and also as an ideal combination ingredient with lutein and zeaxanthin in eye health supplements. It also offers blend formulations of astaxanthin with AREDS2-backed Omega-3 fatty acids for eye health. Such a focused approach toward product application has helped it carve a niche for itself in the market.
23 2010
Aquapharm completes £4.2 million investment
Aquapharm Biodiscovery, a leading marine biotechnology company based at the European Centre for Marine Biotechnology in Oban, Scotland, today announces the close of a £4.2 million investment from existing investors Aescap Venture, Tate & Lyle Ventures, Highlands and Islands Enterprise and NESTA. Alongside the completion of the financing, Aquapharm has appointed the seasoned biotech entrepreneur Simon Best as CEO. Current CEO and founder Andrew Mearns Spragg will take up the role of Chief Technical Officer.
The additional finance will be used towards the further development and commercialisation of Aquapharm’s product portfolio produced from over 7,250 marine micro-organisms. Natural products from this unique source of new biological and chemical diversity are already being exploited commercially with major partners such as Croda Plc and Dr Reddy’s Laboratories in the personal care and pharmaceutical fields respectively. New collaborations in further applications such as nutrition are also in the pipeline.
22 2010
Marine Biodiscovery: Research & Applications Meeting; 15-16 June 2010 – University of Aberdeen, Scotland, UK
This meeting, coinciding with the opening of the new £1.6M Marine Biodiscovery Centre, will address the potential for new products and processes from the marine environment, with a particular emphasis on the technical challenges and realising successful outcomes. This will cover novel pharmaceuticals and high value chemicals such as biomaterials, nutraceuticals and personal care products as well as novel enzymes with unique activities. Academic and industrial aspects will be presented and there will be a showcase for Scottish companies and facilities.
Topics:
- Accessing and assessing marine biodiversity
- Molecular methods to find and express secondary metabolites and enzymes.
- Extraction and isolation of small molecules & modern methods for structural characterisation
- Marine bioinorganic chemistry
- Screening marine natural products
- Applications in the nutraceuticals and personal care market.
- Applications in the high value markets for instance pharmaceuticals and enzymes.
- Taking marine pharmaceuticals to the market
- Marine biomaterials
RSS Feed 
Search
News Archive
Categories
Host
 |
Partners
 |
Sponsors
 |  |
Latest News
- Researchers worry that damage to the oceans could mean some species — and whatever chemicals they produce — will be lost before they’re found
- Neptune Technologies & Bioressources profits rise on krill oil success
- Shellfish Waste May Give Us “Vanishing Plastic”
- Solazyme Delivers 100% Algal-Derived Renewable Jet Fuel to U.S. Navy
- MDPI Publishes New Marine Drugs Issue: Volume 8, Issue 6
Recent Comments
- Константин on Aquapharm completes £4.2 million investment
- Арсений on MOU signed between Universiti Sains Malaysia (USM) and the Rheinische-Friedrich-Wilhelms University in Bonn, Germany, On Marine Biotech Development
- Валентин on Blue Bio Open Innovation (BBOI): Norway and Sweden Collaborate on Joint Marine Biotech Development
- Коля on MOU signed between Universiti Sains Malaysia (USM) and the Rheinische-Friedrich-Wilhelms University in Bonn, Germany, On Marine Biotech Development
- Olha on GRC hosts Marine Natural Products conference in California, Feb 2010
Share Aquapreneur
